Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pertuzumab Biosimilar (Tanvex BioPharma, Inc.), 帕妥珠单抗生物类似药(泰福生技股份有限公司), TX-52 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 01 Feb 2025 |